Find the right fit for you - faster
Get tailored insights about working at Pear Therapeutics in one quick step.
Pear Therapeutics Snapshot
Pear is a place for pioneers: for those with a passion for investigating unchartered territories and boldly advancing medicine and patient treatments. We operate at the intersection of biology and software technology, where researchers and clinicians work side-by-side with software engineers and developers to create the next generation of therapeutics.
Pear Therapeutics discovers, develops, and delivers clinically-validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Every day, we push the boundaries of technology to transform medicine.
Pear Therapeutics discovers, develops, and delivers clinically-validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Every day, we push the boundaries of technology to transform medicine.
Pear Therapeutics is the leader in prescription digital therapeutics. We aim to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has a pipeline of products and product candidates across therapeutic areas, including severe psychiatric and neurological conditions. Our lead product, reSET®, treats Substance Use Disorder and was the first prescription digital therapeutic to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O™, for the treatment of Opioid Use Disorder, received marketing clearance from the FDA in December 2018. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first product submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program and was authorized in March 2020. Our pipeline is focused on product candidates across therapeutic areas to address unmet medical needs and demonstrate clinically relevant treatment effects. For more information, visit us at www.peartherapeutics.com.
* reSET-O™ , reSET® and Somryst® are registered trademarks of Pear Therapeutics, Inc.
* reSET-O™ , reSET® and Somryst® are registered trademarks of Pear Therapeutics, Inc.
